Outlook Therapeutics is trading 15.12% down at $0.75 after investors continued selling following its discounted $55 million public offering, priced at $0.99 per share and warrant.
- The financing adds substantial share dilution and warrants exercisable at $1.10.
- The August 14 earnings update narrowed adjusted losses while maintaining focus on a late-2026 LYTENAVA launch.
- The broader market is nearly flat, making company-specific financing and dilution the clearest explanation.